Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $93.3 million.

  • Entrada Therapeutics' Cash & Equivalents rose 19.52% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 19.52%. This contributed to the annual value of $101.2 million for FY2024, which is 49.72% up from last year.
  • Per Entrada Therapeutics' latest filing, its Cash & Equivalents stood at $93.3 million for Q3 2025, which was up 28.70% from $72.5 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Cash & Equivalents peaked at $227.6 million during Q1 2023, and registered a low of $45.2 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $78.0 million (2024), whereas its average is $99.4 million.
  • In the last 5 years, Entrada Therapeutics' Cash & Equivalents soared by 168.96% in 2023 and then plummeted by 69.94% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Cash & Equivalents (Quarterly) stood at $45.2 million in 2022, then spiked by 49.70% to $67.6 million in 2023, then skyrocketed by 49.72% to $101.2 million in 2024, then rose by 19.52% to $93.3 million in 2025.
  • Its last three reported values are $93.3 million in Q3 2025, $72.5 million for Q2 2025, and $67.8 million during Q1 2025.